SciClone Pharmaceuticals (Holdings) (HKSE:06600) Median PS Value : HK$0.00 (As of Jun. 07, 2024)

View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. SciClone Pharmaceuticals (Holdings)'s Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$5.306. SciClone Pharmaceuticals (Holdings)'s 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is HK$0.00.

As of today (2024-06-07), SciClone Pharmaceuticals (Holdings)'s share price is HK$18.64. SciClone Pharmaceuticals (Holdings)'s Median PS Value is HK$0.00. Therefore, SciClone Pharmaceuticals (Holdings)'s Price to Median PS Value for today is 0.00.

The historical rank and industry rank for SciClone Pharmaceuticals (Holdings)'s Median PS Value or its related term are showing as below:

HKSE:06600's Price-to-Median-PS-Value is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.815
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

SciClone Pharmaceuticals (Holdings) Median PS Value Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Median PS Value Chart

SciClone Pharmaceuticals (Holdings) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Median PS Value

Get a 7-Day Free Trial

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Median PS Value	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of SciClone Pharmaceuticals (Holdings)'s Median PS Value

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals (Holdings)'s Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SciClone Pharmaceuticals (Holdings)'s Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals (Holdings)'s Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals (Holdings)'s Price-to-Median-PS-Value falls into.

SciClone Pharmaceuticals (Holdings) Median PS Value Calculation

SciClone Pharmaceuticals (Holdings)'s Median PS Value for today is calculated as

Median PS Value	=	Revenue per Share (TTM)	*	10-Year Median PS Ratio
	=	5.306	*	0
	=	0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SciClone Pharmaceuticals (Holdings)'s Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$5.306.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

SciClone Pharmaceuticals (Holdings)'s Price to Median PS Value for today is calculated as

Price to Median PS Value	=	Share Price	/	Median PS Value
	=	18.64	/	0.00
	=

SciClone Pharmaceuticals (Holdings) Median PS Value Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Median PS Value

Traded in Other Exchanges

N/A

Address

381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN

Website

https://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Zhao Hong	2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang	2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited	2501 Other
Ascendent Capital Partners Ii Gp Limited	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p.	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p.	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited	2101 Beneficial owner
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Bank Of China Limited	2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited	2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines